Terumo Blood and Cell Technologies and FUJIFILM Irvine Scientific have announced a strategic partnership to optimise T cell expansion protocols, combining Terumo BCT’s Quantum Flex Cell Expansion System with FUJIFILM’s PRIME-XV T Cell Expansion Media. This collaboration addresses significant manufacturing challenges faced by cell therapy developers, particularly those in early-stage development.
Monheim-based Cube Biotech has acquired IBA Lifesciences in a strategic transaction that combines two significant players in protein research and production technologies. The acquisition, announced on 13 January 2025, creates an entity with enhanced capabilities in membrane protein production, purification, and stabilisation technologies.
Cambridge-based organ-on-chip (OOC) technology developer CN Bio has established a strategic partnership with Japanese distributor Primetech Corporation to expand access to its microphysiological systems throughout Japan. The collaboration arrives as the Japanese OOC market demonstrates significant growth potential, with projections indicating a market value of £22.1M by 2030, representing a compound annual growth rate of […]
Cambridge-based Abselion has secured £6.6 million in Series A financing to commercialise its Amperia protein analyser system, which enables rapid at-line quantification of antibodies, AAVs and other proteins from crude samples. The funding round was led by M Ventures, with participation from new and existing investors.
Two prominent European biospecimen and life sciences companies have combined to strengthen research capabilities across Europe and North America, marking significant expansion in biospecimen services and stem cell research sectors.
A new automated screening technology developed by Japanese researchers enables rapid identification of drug candidates by tracking molecular behaviour within cells, offering significant implications for therapeutic development.
Finnish researchers have developed a high-throughput screening pipeline that enables simultaneous analysis of multiple drug responses in primary tumour samples at single-cell resolution, offering new possibilities for personalised cancer therapy.
Researchers at the University of Bonn have developed an artificial intelligence system that can predict chemical structures of compounds capable of binding to multiple protein targets, potentially streamlining the discovery of more effective therapeutic agents.
Researchers at Linköping University have developed an improved version of the AI protein structure prediction tool AlphaFold, enabling analysis of larger protein complexes and integration of experimental data. The advancement marks a significant step forward in protein research and drug development.
New biosafety level 2 laboratories to support enzyme development
November 2025
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.